Merck/Ridgeback’s Lagevrio Could Get Another Chance As Others Face Limitations

New Analysis Shows No COVID-19 At Days 3 Or 5

 
• By Alaric DeArment
Merck & Co. and Ridgeback are presenting a new analysis at ECCMID for Lagevrio in COVID-19 • Source: Alamy

More from COVID-19

More from Scrip